All articles tagged with #kenvue
Following Hayden Panettiere’s death and resurfaced remarks about postpartum depression, fans launched a boycott of Neutrogena, dragging down its parent company Kenvue’s stock; Panettiere had said Neutrogena ended her contract after she spoke about postpartum depression on Live! with Kelly and Michael in 2015, a detail she discussed in her 2026 memoir.
Texas Attorney General Ken Paxton is seeking to block Tylenol maker Kenvue from paying $400 million in dividends amid a lawsuit claiming the company failed to disclose autism risks associated with the medication, using a rare legal move to protect potential assets for legal liabilities. The case is part of broader political and health debates surrounding Tylenol and autism, with the company denying the allegations and criticizing the lawsuit as politically motivated.
The proposed merger between Kimberly-Clark and Kenvue, both Dividend Aristocrats, faces market skepticism due to valuation concerns, Kenvue's recent stock decline, and potential liabilities from Tylenol litigation, leading some to believe that avoiding the deal might be better for dividend investors.
Kimberly-Clark's proposed merger with Kenvue faces skepticism due to Kenvue's weakening sales and legal liabilities, leading to a significant stock decline and potential activist opposition, raising doubts about the deal's approval and completion.
Kimberly-Clark is acquiring Kenvue for nearly $50 billion, aiming to create a global health and wellness leader, but the market reacts negatively due to legal risks and Kenvue's stagnant sales. Kenvue's stock rose 15% post-announcement, while Kimberly-Clark's fell 13%, reflecting investor concerns about the deal's valuation and potential legal liabilities.
Kimberly-Clark is acquiring Kenvue, the maker of Tylenol and other consumer health products, in a nearly $49 billion deal, aiming to create a global health and wellness leader amid challenges faced by Kenvue following controversial claims linking acetaminophen to autism.
The article highlights the stocks that are experiencing the most movement today, including Kenvue, Kimberly-Clark, Amazon, Berkshire Hathaway, Palantir, IREN, and Cipher Mining, among others.
Kimberly-Clark is acquiring Kenvue, the maker of Tylenol, for $40 billion, creating a leading health and wellness company with over $32 billion in revenue, despite legal and market challenges related to Tylenol's safety concerns and recent financial struggles of Kenvue.
Kimberly-Clark plans to acquire Kenvue, the maker of Tylenol, for over $40 billion, creating one of the largest consumer health companies in the U.S., with the deal expected to close in late 2026 and offering significant cost savings despite recent legal and regulatory challenges faced by Kenvue.
Kimberly-Clark is set to acquire Kenvue in a $48.7 billion deal, creating a major consumer staples company with brands like Huggies, Kleenex, Band-Aid, and Tylenol, expected to close in late 2026, amid industry shifts and strategic realignments.
Kimberly-Clark announced a nearly $50 billion acquisition of Kenvue, Tylenol’s parent company, creating a consumer products giant with 10 billion-dollar brands and $32 billion in annual revenue, expected to close in the second half of next year.
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging they concealed the potential link between Tylenol (acetaminophen) and autism/ADHD, despite government confirmation of risks and public warnings by Trump. Kenvue defends Tylenol's safety, while Johnson & Johnson disclaims liability, leading to stock declines for both companies.
Kenvue's stock dropped over 13% due to a new lawsuit alleging its baby powder caused cancer, stemming from old allegations linked to talc-based products inherited from Johnson & Johnson, despite the company switching to cornstarch in 2020.
Kenvue's stock dropped 10% after a UK lawsuit accused Johnson & Johnson and Kenvue UK of selling asbestos-contaminated baby powder linked to serious diseases, raising potential financial concerns amid ongoing litigation and previous US lawsuits. Johnson & Johnson denies the allegations, and the case adds to the company's legal challenges related to talc products.
Kenvue, the company behind Tylenol, is facing a public relations crisis after President Trump suggested unproven links between Tylenol use during pregnancy and autism, leading to stock decline and increased scrutiny, despite scientific evidence indicating no such link. The company is actively trying to reassure consumers and defend the safety of its product amid legal and public challenges.